Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine

"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."

GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses